Publication:
Eculizumab for atypical hemolytic-uremic syndrome. How long should we maintain it?

Simple item page
dc.contributor.authorNaranjo Muñoz, Javier
dc.contributor.authorGarcia Garcia-Doncel, Ana
dc.contributor.authorMontero Escobar, María Elisa
dc.contributor.authorVillanego Fernandez, Florentino
dc.contributor.authorMillán Ortega, Irene
dc.contributor.authorCeballos Guerrero, Manuel
dc.date.accessioned2023-01-25T13:31:46Z
dc.date.available2023-01-25T13:31:46Z
dc.date.issued2019-02-21
dc.identifier.doi10.1016/j.nefro.2019.01.001
dc.identifier.essn2013-2514
dc.identifier.pmid30798995
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.nefro.2019.01.001
dc.identifier.urihttp://hdl.handle.net/10668/13621
dc.issue.number4
dc.journal.titleNefrologia
dc.journal.titleabbreviationNefrologia (Engl Ed)
dc.language.isoen
dc.language.isoes
dc.organizationHospital Universitario Puerta del Mar
dc.organizationHospital Universitario Puerta del Mar
dc.page.number440-442
dc.pubmedtypeCase Reports
dc.pubmedtypeLetter
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.meshAdult
dc.subject.meshAntibodies, Monoclonal, Humanized
dc.subject.meshAtypical Hemolytic Uremic Syndrome
dc.subject.meshComplement Inactivating Agents
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshTime Factors
dc.titleEculizumab for atypical hemolytic-uremic syndrome. How long should we maintain it?
dc.title.alternativeEculizumab en el síndrome hemolítico urémico atípico. ¿Hasta cuándo mantenerlo?
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number39
dspace.entity.typePublication

Files

Collections

SAS - Hospital Universitario Puerta del Mar

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía